# Post-Kala-Azar Dermal Leishmaniasis

> NEET-PG Dermatology notes on post-kala-azar dermal leishmaniasis, its macular, papular and nodular forms, relevance to elimination in India and miltefosine.

- Canonical URL: https://prepelephant.com/topics/neet-pg/dermatology/post-kala-azar-dermal-leishmaniasis
- Exam / course: NEET-PG · Subject: Dermatology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: IADVL Textbook of Dermatology; Fitzpatrick's Dermatology; National Kala-azar Elimination Programme guidelines
- How to cite: "Post-Kala-Azar Dermal Leishmaniasis", PrepElephant, https://prepelephant.com/topics/neet-pg/dermatology/post-kala-azar-dermal-leishmaniasis

## Direct answer

Post-kala-azar dermal leishmaniasis is a chronic skin complication that appears after visceral leishmaniasis caused by Leishmania donovani has been treated or apparently cured. It presents as hypopigmented or erythematous macules, papules or nodules, usually on the face, arms and trunk, and the untreated patient remains a reservoir for transmission. Oral miltefosine for about 12 weeks is the standard treatment in India, and these lesions are a key elimination target.

## What you must remember

- **Causative organism:** Leishmania donovani, transmitted in India by the sandfly Phlebotomus argentipes.
- **Timing:** skin lesions usually emerge months to a few years after visceral disease, and occasionally without a recognised earlier episode of kala-azar.
- **Macular form:** hypopigmented or erythematous macules, often the first presentation, which can be confused with leprosy or pityriasis alba.
- **Papular and nodular forms:** papules and nodules that may coalesce, with the nodular type usually carrying the heaviest parasite burden.
- **Diagnosis:** skin smear or biopsy showing amastigotes, supported by a history of kala-azar; macular lesions often yield few parasites, so a negative smear does not exclude the disease.
- **Drug of choice in India:** miltefosine given orally for about 12 weeks, with weight-based dosing; WHO now also endorses shorter liposomal amphotericin B regimens, so check current national guidance.
- **Pregnancy caution:** miltefosine is teratogenic, so effective contraception is required during treatment and for a period afterwards.

## Clinical workup of a suspected PKDL patient

A 19-year-old who was treated for visceral disease two years ago now has hypopigmented macules on the cheeks and forearms, with no fever or splenomegaly. The workup links the skin findings back to the earlier systemic illness and to the parasite.

1. **Take the kala-azar history:** Ask about previous visceral leishmaniasis, its treatment and any relapse, because the skin lesions follow the systemic disease. A history of residence in an endemic district strengthens the suspicion.
2. **Examine the lesion pattern:** Document whether the lesions are macular, papular or nodular, and map their distribution across the face, limbs and trunk. Macules on the face are the usual starting point.
3. **Exclude leprosy and other mimics:** Hypopigmented macules need sensory testing and a leprosy evaluation, since both conditions can coexist. Pityriasis alba and tinea versicolor also enter the differential.
4. **Obtain parasitological proof:** Take a slit smear or a punch biopsy for Leishmania amastigotes, and use PCR where available. Parasites are scanty in macular lesions, so repeat sampling from a fresh papule or nodule may be needed.
5. **Start miltefosine:** Give oral miltefosine for about 12 weeks with weight-based dosing, ensuring pregnancy is excluded and contraception is arranged before the first dose. Monitor for gastrointestinal upset and renal function.
6. **Report and follow up:** Record the case under the national programme, and review the patient for lesion resolution and relapse. Contacts in the household are screened for kala-azar as part of the programme.

## Where the exam tries to catch you

PKDL questions test the link between the systemic disease, the skin lesions and the programme's elimination logic.

- **Trap:** labelling hypopigmented macules as leprosy and starting multidrug therapy without asking about kala-azar. **Correct:** a prior history of visceral leishmaniasis and a parasitological finding establish PKDL, although leprosy can coexist and must be excluded.
- **Trap:** declaring a kala-azar patient cured and stopping follow-up. **Correct:** skin lesions can emerge after apparent cure, so the patient is reviewed for skin changes after treatment.
- **Trap:** giving miltefosine without a pregnancy test. **Correct:** miltefosine is teratogenic, so pregnancy must be excluded and contraception ensured.
- **Trap:** treating PKDL as a harmless cosmetic problem. **Correct:** untreated PKDL acts as a reservoir for sandfly transmission, which is why it is central to kala-azar elimination in India.

## Frequently asked questions

### Why is post-kala-azar dermal leishmaniasis important for elimination in India?

Post-kala-azar dermal leishmaniasis is important for elimination because its skin lesions harbour parasites that sandflies can take up and transmit. Identifying and treating these patients is therefore a core activity of the National Kala-azar Elimination Programme.

### Which drug is used for post-kala-azar dermal leishmaniasis in India?

Oral miltefosine given for about 12 weeks is the standard treatment for post-kala-azar dermal leishmaniasis in India, with weight-based dosing. Its use requires pregnancy to be excluded, since miltefosine is teratogenic.

### How does post-kala-azar dermal leishmaniasis differ from visceral leishmaniasis?

Post-kala-azar dermal leishmaniasis presents with skin lesions and usually without fever, splenomegaly or pancytopenia, whereas visceral leishmaniasis is a systemic illness. The skin disease follows the systemic disease and reflects persistence of parasites in the dermis.

### Why can a negative skin smear not rule out post-kala-azar dermal leishmaniasis?

Macular lesions often contain very few parasites, so a single skin smear can be negative despite active disease. Repeat sampling from a papule or nodule, or a biopsy, improves the chance of demonstrating amastigotes.